Abstract The aim of this study was to evaluate the role of S100A4 as a biomarker in patients with early rheumatoid arthritis (RA). S100A4 levels were measured in 59 patients with early RA and in 41 healthy controls. The association between the S100A4 levels and the treatment outcome after 12 months was determined using multivariate regression analysis. Serum S100A4 levels were significantly higher in the patients with early RA than in the healthy subjects and significantly decreased after 3 months of treatment. Diseases activity at 12 months was significantly higher in female patients who had initially high levels of S100A4. Persistently high S100A4 levels predicted poor treatment outcome and S100A4 may thus represent promising biomarker for assessing treatment response in patients with RA.

Institute of Rheumatology Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16000463

003      

CZ-PrNML

005      

20200205144645.0

007      

ta

008      

160108s2015 enk f 000 0|eng||

009      

AR

024    7_

$a 10.3109/1354750X.2014.989544 $2 doi

035    __

$a (PubMed)25489637

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a enk

100    1_

$a Šenolt, Ladislav, $u Institute of Rheumatology , Prague , Czech Republic . $d 1976- $7 xx0056558

245    10

$a High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort / $c L. Šenolt, LA. Cerezo, B. Šumová, O. Pecha, L. Pleštilová, Š. Forejtová, O. Růžičková, M. Hušáková, J. Závada, K. Pavelka, J. Vencovský, H. Mann,

520    9_

$a Abstract The aim of this study was to evaluate the role of S100A4 as a biomarker in patients with early rheumatoid arthritis (RA). S100A4 levels were measured in 59 patients with early RA and in 41 healthy controls. The association between the S100A4 levels and the treatment outcome after 12 months was determined using multivariate regression analysis. Serum S100A4 levels were significantly higher in the patients with early RA than in the healthy subjects and significantly decreased after 3 months of treatment. Diseases activity at 12 months was significantly higher in female patients who had initially high levels of S100A4. Persistently high S100A4 levels predicted poor treatment outcome and S100A4 may thus represent promising biomarker for assessing treatment response in patients with RA.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a revmatoidní artritida $x krev $x farmakoterapie $x patologie $7 D001172

650    _2

$a biologické markery $x krev $7 D015415

650    _2

$a studie případů a kontrol $7 D016022

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a metastázy nádorů $7 D009362

650    _2

$a proteiny S100 $x krev $7 D009418

650    _2

$a výsledek terapie $7 D016896

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Andrés Cerezo, Lucie $7 xx0143527

700    1_

$a Šumová, Barbora $7 xx0214573

700    1_

$a Pecha, Ondřej

700    1_

$a Pleštilová, Lenka $7 xx0160053

700    1_

$a Forejtová, Šárka, $d 1963- $7 xx0061013

700    1_

$a Růžičková, Olga $7 xx0093659

700    1_

$a Hušáková, Markéta, $d 1977- $7 xx0143346

700    1_

$a Závada, Jakub $7 xx0160054

700    1_

$a Pavelka, Karel, $d 1954- $7 jn99240000847

700    1_

$a Vencovský, Jiří, $d 1953- $7 jo20000080529

700    1_

$a Mann, Heřman, $d 1973- $7 nlk20010095506

773    0_

$w MED00000752 $t Biomarkers biochemical indicators of exposure, response, and susceptibility to chemicals $x 1366-5804 $g Roč. 20, č. 1 (2015), s. 47-51

856    41

$u https://pubmed.ncbi.nlm.nih.gov/25489637 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160108 $b ABA008

991    __

$a 20200205145033 $b ABA008

999    __

$a ok $b bmc $g 1102744 $s 924669

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 20 $c 1 $d 47-51 $e 20141209 $i 1366-5804 $m Biomarkers $n Biomarkers $x MED00000752

GRA    __

$a NT13698 $p MZ0

LZP    __

$a Pubmed-20160108